A deleterious role for Th9/IL-9 in hepatic fibrogenesis

Area of Science:

• Immunology
• Hepatology
• Cell Biology

Background:

• T helper 9 (Th9) cells are a subset of T helper cells implicated in autoimmune diseases.
• Hepatic fibrosis is a significant pathological condition characterized by excessive accumulation of extracellular matrix in the liver.
• The specific role of Th9 cells and their associated cytokine, interleukin-9 (IL-9), in the pathogenesis of hepatic fibrosis remains to be fully elucidated.

Purpose of the Study:

• To investigate the role of Th9 cells and IL-9 in the development and progression of hepatic fibrosis.
• To quantify Th9 and Th17 cell populations and related cytokine levels in patients with chronic hepatitis B (CHB) and liver cirrhosis (LC).
• To explore the therapeutic potential of targeting the Th9/IL-9 pathway in a mouse model of hepatic fibrosis.

Main Methods:

• Quantification of Th9 and Th17 cells in peripheral blood of CHB patients, LC patients, and healthy controls.
• Measurement of plasma and liver tissue concentrations of IL-9, IL-17, and other inflammatory cytokines (TNF-α, IL-6, IL-4, IL-21, TGF-β1, IFN-γ) using ELISA and other assays.
• In vivo studies involving a mouse model of hepatic fibrosis with IL-9 neutralization to assess therapeutic effects on fibrosis, stellate cell activation, immune cell frequencies, and cytokine expression.

Main Results:

• Elevated percentages of Th9 and Th17 cells, along with increased plasma concentrations of IL-9 and IL-17, were observed in CHB and LC patients compared to healthy controls.
• Mice with hepatic fibrosis exhibited significantly higher splenic Th9 and Th17 cell counts and elevated IL-9 and IL-17A levels in plasma and liver tissue.
• Neutralization of IL-9 in mice significantly ameliorated hepatic fibrosis, reduced hepatic stellate cell activation, decreased Th9, Th17, and Th1 cell frequencies, and suppressed pro-inflammatory and profibrotic cytokine expression.

Conclusions:

• The Th9/IL-9 axis plays a detrimental role in promoting hepatic fibrosis and exacerbating liver disease progression.
• Targeting Th9 cells and IL-9 presents a promising therapeutic strategy for the treatment of hepatic fibrosis.
• Further research into Th9/IL-9 based immunotherapies could lead to novel treatments for liver fibrosis.